[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570719":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":51,"collaborators":28,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":28,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":28,"enrollmentInfo":62,"targetDuration":28,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":28,"overallStatus":71,"whyStopped":28,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University Hospitals of North Midlands NHS Trust","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment phase A","EXPERIMENTAL","Methenamine Hippurate 1g BD for 6 months",[13],"Drug: Methenamine Hippurate 1g BD",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment phase B","Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months",[18],"Drug: Methenamine Hippurate 1g BD + Vitamin C 1g BD",{"label":20,"type":10,"description":21,"interventionNames":22},"Treatment phase C","Methenamine 1g BD for 6 months",[13],[24,29],{"type":25,"name":26,"description":11,"armGroupLabels":27,"otherNames":28},"DRUG","Methenamine Hippurate 1g BD",[9,20],null,{"type":25,"name":30,"description":16,"armGroupLabels":31,"otherNames":28},"Methenamine Hippurate 1g BD + Vitamin C 1g BD",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":28,"email":37},"Aviva Ogbolosingha","CONTACT","01782 675380","aviva.ogbolosingha@uhnm.nhs.uk",[39],{"facility":5,"status":28,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":28},"Stoke-on-Trent","Staffordshire","ST4 6QG","United Kingdom","UK",{"type":46,"coordinates":47},"Point",[48,49],-2.18538,53.00415,{"lat":49,"lon":48},{"type":52,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100570719","early-phase-1-vitamin-c-and-hiprex-in-ruti-100570719",false,"NCT06710899","Vitamin C and Hiprex in rUTI","Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study","Inclusion Criteria:\n\n* Female\n* Age ≥18 years\n* Recurrent proven UTI, defined as \"two or more proven infections in six months or three or more infections in six months\"\n* Willing and able to give fully informed consent\n* Patients suitable for prophylaxis following discussion with their clinician.\n* No contra-indications to treatment with methenamine hippurate or Vitamin C\n* All women will have undergone standard diagnostic work-up and have followed routine conservative UTI prevention measures.\n* A working email address to be used to submit urine pH results\n* Willing and able to comply with the study procedures\n* Females of childbearing potential must be willing to use a highly effective method of contraception (hormonal or barrier method of birth control; abstinence; sterilisation or vasectomised partner)\n\nExclusion Criteria:\n\n* Males\n* Women who are pregnant or breast-feeding\n* Contraindications to methenamine hippurate as described in BNF: known allergy, gout, severe metabolic acidosis, severe dehydration, eGFR less than 10 ml\u002Fmin, severe hepatic impairment\n* Currently using vitamin C containing supplement or cranberry extract tablets\n* Women using urinary alkalinisation agents, e.g potassium citrate, sodium bicarbonate\n* Currently receiving any form of bladder instillation or intradetrusor Onabotulinum Toxin A injections\n* Patients already on low-dose antibiotics or methenamine hippurate (due to delay that will be incurred by 3-month washout period)\n* Indwelling urinary catheter in situ or performing clean intermittent self-catheterisation\n* Correctable urinary tract abnormalities, e.g., urinary tract calculi, urinary retention\n* Formation of ileal conduit or augmented bladder\n* Neurogenic bladder dysfunction\n* Hyperoxaluria","FEMALE","18 Years",{"count":63,"type":64},20,"ESTIMATED","INTERVENTIONAL",[67],"EARLY_PHASE1","A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women",[70],"Urinary Tract Infections","NOT_YET_RECRUITING","2026-02-10",{"date":74,"type":75},"2026-02-11","ACTUAL",{"date":77,"type":64},"2027-01",{"date":79,"type":64},"2028-01",{"name":5,"class":6},1]